Precigen, Inc.
precigen.comWhat Do They Do?
Develops precision medicines for patients with cancer, autoimmune disorders and infectious diseases, and sells genetically engineered miniature swine models and research services to industry and academic researchers.
10-K for FY2025, filed Mar 25, 2026We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives…View ↗
Precigen's most advanced programs based on the AdenoVerse immunotherapy platform include: (i) Papzimeos, a non-replicating adenoviral…View ↗
Precigen Exemplar provides porcine research models and services that aid scientists in the understanding of human disease mechanisms and…View ↗
How Do They Make Money?
Precigen sells Papzimeos through specialty distributors to medical centers, hospitals and specialty pharmacies, and sells miniature swine models and research services through Exemplar; product revenue is counted on delivery and service revenue as services are provided. Papzimeos payments are generally due 60 to 127 days after sale; Exemplar invoices are typically due within 30 days.
10-K for FY2025, filed Mar 25, 2026In 2025, the Company received FDA approval for Papzimeos and initiated commercial sales during the fourth quarter of 2025. Product revenue…View ↗
The Company generates product and service revenues through Exemplar, which consists of the development and sale of genetically engineered…View ↗
Exemplar revenues primarily consist of over‑time service revenue and point‑in‑time product sales, whereas Papzimeos is recognized…View ↗
-
10-K for FY2025, filed Mar 25, 2026
FY2025 revenue by product or service ↗
$9.7M
-
10-K for FY2025, filed Mar 25, 2026
$9.7M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenues, net
Sold outright
10-K for FY2025, filed Mar 25, 2026 |
41% |
Product revenues, net, FY2025
$4M Sources
|
Sold outright |
|
Service revenues
Recurring
10-K for FY2025, filed Mar 25, 2026 |
40% |
Service revenues, FY2025
$3.9M Sources
|
Recurring |
Who Are Their Customers?
Specialty distributors supply Papzimeos to medical centers, hospitals and specialty pharmacies. Exemplar sells models and services to industry and academic researchers.
10-K for FY2025, filed Mar 25, 2026
Do Revenues Turn Into Profits?
No. It lost $250.6M in FY2025.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
$20.1MView ↗
- ▲ Now profitable
- vs −$26.6M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 4, 2026
Open tableView ↗
Shrinking. Revenue fell 32% in 4 years, from $14.3M in FY2021 to $9.7M in FY2025, about 9% a year.
From pipeline to commercial product
The earlier report described Precigen as discovery- and clinical-stage, with a pipeline of candidates; the latest describes it as commercial-stage, with Papzimeos approved for sale.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 25, 2026
Who Do They Compete With?
Competes with INOVIO Pharmaceuticals, BioNTech, PDS Biotechnology, NeoTrail Therapeutics, Nykode Therapeutics, ViciniVax, Cellid, Bavarian Nordic, Kite, Iovance, Bristol-Myers Squibb, Merck, Regeneron Pharmaceuticals, Anixa Biosciences, US WorldMeds, Essen Biotech, Senti Bio, Allogene Therapeutics, Arsenal Biosciences, and Arcellx
10-K for FY2025, filed Mar 25, 2026While we believe that our FDA-approved product Papzimeos for the treatment of RRP, is based on a novel design of antigen targeting HPV6 and…View ↗
Loading...
